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Abstract
Background: Limbic encephalitis was originally described as a rare clinical neuropathological entity involving
seizures and neuropsychological disturbances. In this report, we describe cerebral patterns visualized by positron
emission tomography in a patient with limbic encephalitis and cholangiocarcinoma. To our knowledge, there is no
other description in the literature of cerebral positron emission tomography findings in the setting of limbic
encephalitis and subsequent diagnosis of cholangiocarcinoma.
Case presentation: We describe a case of a 77-year-old Caucasian man who exhibited persistent cognitive
changes 2 years before his death. A cerebral scan obtained at that time by 2-deoxy-2-[fluorine-18]fluoro-D-glucose
integrated with computed tomography-positron emission tomography showed low radiotracer uptake in the
frontal and temporal lobes. Cerebrospinal fluid analysis indicated the presence of voltage-gated potassium channel
antibodies. Three months before the patient’s death, a lymph node biopsy indicated a cholangiocarcinoma, and a
new cerebral scan obtained by 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography-
positron emission tomography showed an increment in the severity of metabolic deficit in the frontal and parietal
lobes, as well as hypometabolism involving the temporal lobes. Two months before the patient’s death, cerebral
metastases were detected on a contrast-enhanced computed tomographic scan. Postmortem examination revealed
a cholangiocarcinoma with multiple metastases including the lungs and lymph nodes. The patient’s brain weighed
1300 g, and mild cortical atrophy, ex vacuo dilation of the ventricles, and mild focal thickening of the cerebellar
leptomeninges, which were infiltrated by neoplastic epithelial cells, were observed.
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Conclusions: These findings support the need for continued vigilance in malignancy surveillance in patients with
limbic encephalitis and early cerebral positron emission tomographic scan abnormalities. The difficulty in early
diagnosis of small tumors, such as a cholangiocarcinoma, is discussed in the context of the clinical utility of early
cerebral hypometabolism detected by 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed
tomography-positron emission tomography in patients with rapidly progressive dementia.
Keywords: Cholangiocarcinoma, Limbic encephalitis, Voltage-gated potassium channel complex antibodies,
Cerebral PET/CT, Whole-body PET/CT
Background
Most patients with limbic encephalitis (LE) associated
with voltage-gated potassium channel complex anti-
bodies (VGKC-Ab) do not have a tumor. The few cases
reported in the literature were associated with thymoma
[1], small cell lung cancer [2], or myeloid leukemia [3].
Cholangiocarcinoma is a rare tumor arising from either
intrahepatic or extrahepatic bile ducts [4]. The presence
of brain metastasis due to cholangiocarcinoma is a rare
event [4]. To our knowledge, there is no previous report
in the literature describing LE and paraneoplastic associ-
ation with a cholangiocarcinoma.
Case presentation
Our patient was a 77-year-old Caucasian man who, 3
years and 11 months before his death, exhibited sub-
acute polyneuropathy that included large fibers with
autonomic changes. The clinical presentation of the pa-
tient’s polyneuropathy did not allow us to differentiate a
paraneoplastic pathology from an atypical presentation
of diabetic neuropathy. A first episode of focal epileptic
crises occurred 13 months after the polyneuropathy
event. Two years before the patient’s death, an electro-
encephalogram showed epileptic discharges in the right
temporal cortex (Fig. 1). After that, his autonomic sei-
zures became more frequent, and ictal pilomotor erec-
tion was a common observation.
Two years before the patient’s death, a diagnosis of
probable dementia was made. The presence of rapidly
progressive dementia, delusions, and autonomic seizures
with pilomotor erection suggested a preliminary diagno-
sis of limbic encephalopathy. At that time, cerebrospinal
fluid (CSF) analysis including the following was per-
formed: herpes simplex virus (repeated three times with
negative results), varicella zoster virus, cytomegalovirus,
Epstein-Barr virus, HIV, human T-cell lymphotropic
virus 1/2, JC virus, Borrelia burgdorferi (Lyme disease),
Tropheryma whippleii (detected but not confirmed in a
second sample), Treponema pallidum, and Cryptococcus
neoformans. All results of these tests were negative. No
growth of any bacteria or fungi was detected. The pa-
tient’s protein electrophoresis result was also normal.
Fig. 1 Abnormal electroencephalogram obtained 2 years before the death of the patient. The electroencephalogram shows epileptic discharges
from the right temporal lobe
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His 14-3-3 protein test result was negative. The patient
had a slightly reduced amyloid-β42 level (543 pg/ml).
However, his tau protein level was normal (210 pg/ml).
His CSF was also analyzed using an established radio-
immunoassay in a reference laboratory. Intracellular
antibodies (Hu, Ri, Yo, and Ma2) and surface antibodies
(VGKCs KV1.1, KV1.2, and KV1.6) were assessed. Nega-
tive results were obtained for the intracellular antibodies.
According to the relative values provided by the refer-
ence laboratory, the results of the VGKC-Ab test were
positive.
Twenty-three months before the patient’s death, cere-
bral imaging by 2-deoxy-2-[fluorine-18]fluoro-D-glucose
integrated with computed tomography-positron emis-
sion tomography (18F-FDG-PET/CT) was performed ac-
cording to the following acquisition protocol.
Fluorodeoxyglucose (FDG) (±5.3 MBq/kg) was injected
intravenously under euglycemic (6-hour fast, capillary
blood glucose <140 mg/dl) and standardized resting
(eyes open, reduced ambient noise) conditions. After 1
hour of uptake time, images were acquired by positron
emission tomography-computed tomography (PET-CT)
using a Biograph Duo lutetium oxyorthosilicate PET/CT
scanner (Siemens Medical Solutions, Knoxville, TN,
USA), followed by dedicated brain PET-CT image acqui-
sition (10-minute acquisition). Next, three-dimensional
iterative reconstruction was used for the brain PET im-
ages (iterations = 6/subsets = 16/full width at half max-
imum = 2 mm/matrix = 256). Finally, computed
tomographic images were used for attenuation correc-
tion of PET data. The cerebral FDG-PET performed 23
months before the patient’s death showed low FDG
uptake in the frontal and temporal lobes, especially in
the right hemisphere, with relative preservation of the
posterior cingulum (Fig. 2a).
Six months before the patient’s death, he presented
with normal-pressure hydrocephalus. A ventricular peri-
toneum derivation (VPD) was inserted. A small im-
provement in walking was observed, but it lasted no
more than 2 weeks after the VPD implant. Three months
before the patient’s death, a second repeat cerebral
FDG-PET scan using the same acquisition protocol as
before showed diffusely low cerebral glycolytic activity
with a marked increment in the severity of the metabolic
deficit in the frontal and temporal lobes, as well as hypo-
metabolism involving the parietal lobes and posterior
cingulum (Fig. 2b). Three months before the patient’s
death, a biopsy done in the right axillary lymph node in-
dicated a metastatic cholangiocarcinoma. The most
common type of hilar extrahepatic cholangiocarcinoma
is classified into four stages according to the Bismuth
classification [5]. In our patient, this classification was
considered stage IV. Two months before his death, a
contrast-enhanced computed tomographic scan showed
brain metastases in the right parietal cortex (Fig. 3).
A postmortem examination showed a cholangiocarci-
noma with multiple metastases that included the lungs
and lymph nodes. All other organs were studied during
the autopsy, and the only primary neoplasia found was the
cholangiocarcinoma; the other sites were metastatic, all
exhibiting the same morphological aspects as the cholan-
giocarcinoma. The brain weighed 1300 g, and a catheter
was well positioned in the lateral ventricle. There was mild
cortical atrophy, ex vacuo dilation of the ventricles, and
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Fig. 2 Cerebral scans (axial slices, I–IV) obtained by 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography-positron emission
tomography. Cerebral 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography-positron emission tomography was performed
23 months before the patient’s death. a Four representative axial slices (AI–AIV) show decreased fluorodeoxyglucose uptake in the frontal and temporal
lobes and normal uptake in the posterior cingulum and occipital cortex. Note that the hypometabolism in the affected regions is greater in the right
hemisphere. b Cerebral 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography-positron emission tomography performed 3
months before the patient’s death shows the general reduction in radiotracer uptake in the same axial levels (BI–BIV)
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mild focal thickening of the cerebellar leptomeninges,
which were infiltrated by the carcinoma, described as neo-
plastic epithelial cells (Fig. 4). The morphological aspects
were similar to the cholangiocarcinoma seen in the liver,
histopathologically confirming the brain metastasis. There
were no other changes in the cerebral cortex and white
matter, except some thickened, hyalinized microvessels in
the deep white matter with adjacent gliosis and calcifica-
tion of vessel walls in the basal ganglia. Axonal peripheral
neuropathy associated with microangiopathy, possibly re-
lated to diabetes, was also seen.
Discussion
Our patient showed cognitive symptoms with subacute
onset seizures, including frequent autonomic seizures
with motor piloerection. Ictal piloerection seizure has
been considered the predominant seizure type associated
with LE [6]. However, the diagnosis of autoimmune-
mediated LE based on the detection of anti-VGKC-Ab is
not fully supported by recently published guidelines for
diagnosis of autoimmune encephalitis [7]. In fact, the
presence of autoantibodies does not always imply an ac-
curate diagnosis. It should be mentioned that recently
Fig. 3 Contrast-enhanced computed tomographic scan of the patient’s brain. Transaxial image shows a brain metastasis in the right hemisphere
detected 2 months before the patient’s death
a b
Fig. 4 Postmortem analysis. a Cerebral metastasis seen at the subarachnoid space (hematoxylin and eosin stain, original magnification ×100). b
Higher-magnification view the metastatic cells, which show marked pleomorphism, hyperchromasia, and atypia (hematoxylin and eosin
stain, ×200)
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researchers reported that VKGC antibodies identified by
radioimmunoassay in which a complex of brain proteins
(KV1.1 and KVI.2) are labeled does not necessarily indi-
cate an absolute specificity for VGKC. The term voltage-
gated potassium channel complex includes antibodies
against LGI1, CASP, and unknown antigens [8]. In con-
trast to these findings, our patient exhibited a clinical
syndrome that allowed the diagnosis of LE to be made.
However, it would be of interest to have the results of
the complete VGKC complex test. Recently reported in-
formation on VGKC indicates that the inclusion of
values of VGKC may be of less clinical significance, es-
pecially in the context of the absence of LGI1 and CASP
antibodies [9]. Therefore, VGKC antibodies may be mis-
named, and the diagnosis should rely on the presence of
LGI1 and CASP antibodies.
Neuroimaging, especially cerebral FDG-PET, was de-
terminative for the elucidation of our patient’s case. It
would be of interest to identify PET cerebral patterns
that could lead to an early suspicion of a tumor, such as
a cholangiocarcinoma, in patients with rapidly progres-
sive dementia. Because of its size, the tumor may initially
remain undetected. The case of our patient may indicate
that clinical neurological symptoms, together with spe-
cific PET cerebral patterns, may help in the search for
small tumors. Considering these findings, sequential
whole-body PET scans should be an important tool to
be used in vigilance for malignancy at intervals not lon-
ger than 1.5 years.
Risk factors frequently associated with cholangiocarci-
noma include parasitic diseases involving the biliary tree,
preexistent liver and biliary disease, obesity, diabetes,
HIV infection, and toxic exposure [4]. Our patient did
not have any of these risk factors, except for diabetes.
Surgical resection and liver transplant are the effective
treatments available [10]. However, only patients with
early-stage disease benefit from these treatments. Conse-
quently, an early diagnosis is required. Our patient was
in stage IV, which precluded any surgical treatment.
Early confirmation of cholangiocarcinomas can be very
challenging because these lesions often grow longitudin-
ally along the bile duct rather than in a radial direction
away from the bile duct [6]. Imaging techniques such as
CT, ultrasound, and magnetic resonance imaging may be
of limited sensitivity in these cases [6].
Researchers in most FDG-PET studies of patients with
LE have described mesiotemporal hypermetabolism [11].
In contrast, the authors of other reports have described
mesiotemporal hypometabolism in patients with LE even
several months after symptom onset [11, 12]. The vari-
ability in LE imaging data may be due to different auto-
immunological mechanisms mediated by a particular
autoantibody type [13]. In our patient, hypometabolism
was found approximately 2 years before he died.
Different pathological mechanisms underlying LE as-
sociated with antibodies against either intracellular or
surface antigens have been described after the recent
identification of new antineuronal autoantibodies [8].
Previous studies of patients with LE demonstrating hy-
permetabolism in the mesiotemporal region showed that
the patients had positive test results for autoantibodies
against intracellular antigens [14, 15]. In contrast, the
authors of most reports on patients with LE with auto-
antibodies against surface antigens have described nor-
mal metabolism or hypometabolism in mesiotemporal
regions [13]. In this regard, two different pathological
mechanisms have been proposed to explain the findings
of hypometabolism in the mesiotemporal cortex associ-
ated with autoantibodies against surface membrane anti-
gens. First, Hughes et al. [16] suggested that a reduction
in neuronal activity may be associated with a decrease in
the surface density of N-methyl-D-aspartate receptors via
antibody capping and internalization. Second, Baumgart-
ner et al. [13] proposed that PET hypometabolism may
be caused by direct blockade of receptors by cell surface
antibodies. Furthermore, it is hypothesized that these
pathological mechanisms do not induce inflammatory
damage, activation of immune cells, or tissue repair that
would cause a relevant increase in glucose metabolism.
Conclusions
The pattern of cerebral hypometabolism, together with
clinical findings of LE, should direct the search for a
small tumor. Our patient with cholangiocarcinoma also
showed very pronounced mesiotemporal hypometabo-
lism, brain atrophy, and clinical symptoms of LE. This
case supports continued vigilance in malignancy surveil-
lance of patients with LE. We suggest that any patient
presenting with rapidly progressive dementia and cere-
bral PET abnormalities should be investigated for small
tumors, such as a cholangiocarcinoma, using whole-
body PET at intervals not longer than 1.5 years.
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